EGFR and head and neck cancer: Immune biomarker modulation was observed in an phase Ib clinical trial of patients with head and neck cancer treated with neoadjuvant cetuximab, an epidermal growth factor receptor (EGFR)-specific antibody, plus CD137 agonist urelumab [38].